Evidence map›Paper›PMID 41002854›Full record

ArticleBiomimetics (Basel, Switzerland)2025

Improved Multi-Strategy Aquila Optimizer for Engineering Optimization Problems.

Honglin Kan, Yaping Xiao, Zhiliang Gao, Xuan Zhang

Abstract read
In one paragraph

Article in Biomimetics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Honglin KanSchool of Artificial Intelligence, Anhui Polytechnic University, Wuhu 241000, China.
Yaping XiaoSchool of Artificial Intelligence, Anhui Polytechnic University, Wuhu 241000, China.
Zhiliang GaoSchool of Artificial Intelligence, Anhui Polytechnic University, Wuhu 241000, China.
Xuan ZhangSchool of Artificial Intelligence, Anhui Polytechnic University, Wuhu 241000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Aquila Optimizer (AO) is a novel and efficient optimization algorithm inspired by the hunting and searching behavior of Aquila. However, the AO faces limitations when tackling high-dimensional and complex optimization problems due to insufficient search capabilities and a tendency to prematurely converge to local optima, which restricts its overall performance. To address these challenges, this study proposes the Multi-Strategy Aquila Optimizer (MSAO) by integrating multiple enhancement techniques. Firstly, the MSAO introduces a random sub-dimension update mechanism, significantly enhancing its exploration capacity in high-dimensional spaces. Secondly, it incorporates memory strategy and dream-sharing strategy from the Dream Optimization Algorithm (DOA), thereby achieving a balance between global exploration and local exploitation. Additionally, the MSAO employs adaptive parameter and dynamic opposition-based learning to further refine the AO's original update rules, making them more suitable for a multi-strategy collaborative framework. In the experiment, the MSAO outperform eight state-of-the-art algorithms, including CEC-winning and enhanced AO variants, achieving the best optimization results on 55%, 69%, 69%, and 72% of the benchmark functions, respectively, which demonstrates its outstanding performance. Furthermore, ablation experiments validate the independent contributions of each proposed strategy, and the application of MSAO to five engineering problems confirms its strong practical value and potential for broader adoption.

Indexed as

adaptive parameterAquila Optimizerdynamic opposition-based learningrandom sub-dimension update mechanism

Identifiers

PMID41002854
PMCPMC12467012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.